Katherine C. Fuh, MD, PhD, on Ovarian Cancer: New Data on Batiraxcept and Paclitaxel
2024 ASCO Annual Meeting
Katherine C. Fuh, MD, PhD, of the University of California, San Francisco, discusses phase III findings of the AXLerate-OC trial, showing that batiraxcept with paclitaxel compared to paclitaxel alone improved progression-free and overall survival in patients with platinum-resistant recurrent ovarian cancer whose tumors were AXL-high in an exploratory analysis (LBA5515).
Transcript
Disclaimer: This video transcript has not been proofread or edited and may contain errors.
So most ovarian cancers will become treatment resistant, in particular platinum resistant. We identified AXL receptor tyrosine kinase that's actually expressed in these platinum-resistant ovarian cancers. A targeted therapy was developed named batiraxcept or AVB-500, which actually is a fusion protein that targets GAS6's ligand. So instead of the GAS6 ligand binding to the membrane AXL receptor, this batiraxcept will bind to that GAS6 ligand so that receptor on the tumor will never be activated.
So a phase three trial that we presented talked about GOG-3059 or ENGOT OV-66, AXLerate-OC. This really was focusing on the question, if we give our patients who have platinum-resistant ovarian cancer weekly paclitaxel, which is the standard of care, compared to weekly paclitaxel with batiraxcept, would they actually improve in terms of progression-free survival as a primary endpoint and overall survival as a secondary? We also did perform exploratory endpoints looking at the expression of our tumors for AXL as well as GAS6 and then other exploratory blood markers like serum [inaudible 00:01:15] and GAS6 ratio.
Our findings did show that there was similar progression-free survival between those patients who received the standard of care weekly paclitaxel compared to those with batiraxcept with weekly paclitaxel in both progression-free survival and overall survival, about 5 months for PFS and 14 months for OS. When we actually did the exploratory analysis looking at the AXL-high tumors, we did see a difference for those patients who actually had high AXL in their tumor, which is about 80% intensity. They actually benefited from the receiving batiraxcept and paclitaxel compared to paclitaxel alone. We saw this both in progression-free survival and overall survival.
So this really leads us to ask the next questions in terms of, can we actually develop perhaps this biomarker for AXL? Can we actually target this biomarker and use this biomarker targeted therapy in the future by using this batiraxcept or another AXL inhibitor in combination with paclitaxel for our patients with platinum-resistant ovarian cancer? So in the future, we would like to see if those patients with high-AXL tumors could actually benefit from an AXL inhibitor in platinum-resistant ovarian cancer and really utilize this AXL expression to help focus in on the patients who actually might not benefit from standard of care and may actually benefit from a combination with the AXL inhibitor.
The ASCO Post Staff
Mazyar Shadman, MD, MPH, of Fred Hutchinson Cancer Center, discusses a network meta-analysis showing that zanubrutinib appears to be the most efficacious Bruton’s tyrosine kinase (BTK) inhibitor for patients with high-risk relapsed or refractory chronic lymphocytic leukemia. It offers delayed disease progression and favorable survival and response, compared with alternative BTK inhibitors (Abstract 7048).
The ASCO Post Staff
Reshma Jagsi, MD, DPhil, of Emory University Winship Cancer Institute, and Christian F. Singer, MD, MPH, of the Medical University of Vienna, discuss the MUC-1 vaccine tecemotide. When added to standard neoadjuvant systemic therapy for patients with early-stage breast cancer, this vaccine improved distant relapse–free and overall survival rates. Despite the exploratory nature of this observation, says Dr. Singer, this is the first long-term survival benefit of an anticancer vaccine in breast disease reported to date (Abstract 587).
The ASCO Post Staff
Joshua D. Brody, MD, of the Icahn School of Medicine at Mount Sinai, discusses results from the EPCORE NHL-2 study, which was designed to evaluate the safety and efficacy of epcoritamab-bysp plus rituximab and lenalidomide in the first-line setting for patients with follicular lymphoma and to assess epcoritamab as maintenance therapy in this population (Abstract 7014).
The ASCO Post Staff
Jean-Marc Classe, MD, PhD, of France’s Nantes Université, discusses phase III results showing that systematic lymphadenectomy should be omitted in patients with advanced epithelial ovarian cancer with clinically negative lymph nodes, as well as those undergoing neoadjuvant chemotherapy and interval complete surgery (LBA5505).
The ASCO Post Staff
Tony S.K. Mok, MD, of The Chinese University of Hong Kong, discusses phase III findings from the KRYSTAL-12 study, which showed that adagrasib improved progression-free survival and overall response rate over docetaxel in patients with locally advanced or metastatic non–small cell lung cancer harboring a KRAS G12C mutation who had previously received a platinum-based chemotherapy with anti–PD-(L)1 treatment.